Liu Q, Hou L, Zhao Y, Yang H, Mo Z, Yu F. Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer. Clinics. 2023;78: 100291. doi:10.1016/